Skip to main content
OpenTrials
Completed

NCT Number: NCT03436979

The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse

The objective of the study is to assess the long term safety, durability of clinical effectiveness and cost effectiveness of the NeuGuide™ system when used for vaginal colpopexy in the treatment of uterine prolapse.

Completed

Looking for future studies?

Notify Me

Key information

Age range

36 year–84 year

Sex eligibility

Female

Study type

Observational

Primary location

Krankenhaus Waldfriede, Berlin-Zehlendorf, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with POP-Q C point greater than (-) 1 cm.
  • Patients who have previously had a partial hysterectomy in which the cervix is intact may be included in this study.
  • Non-pregnant female (female of child bearing potential must have a negative pregnancy test).
  • Patient understands the nature and potential hazards of the procedure and provides written informed consent prior to any study specific assessments.
  • Patient is able to complete written questionnaires.
  • Patient is willing and able to comply with the specified study requirements and follow-up assessments, and can be contacted by telephone.

Exclusion criteria

  • Known diagnosis of reproductive tract abnormalities.
  • Prior pelvic radiation therapy, any malignancy or active pelvic inflammatory disease.
  • Known history of severe Pelvic Inflammatory Disease (PID).
  • Prior total hysterectomy.
  • Prior pelvic prolapse surgery using synthetic mesh.
  • Pathological PAP in the past year.
  • Moderate or severe bacterial cervicitis.
  • Moderate or severe pelvic pain (> 3 on VAS).
  • Severe morbid obesity (BMI >45).
  • Temperature > 38°C (oral or equivalent), sepsis, or active infection requiring IV anti-microbial treatment.
  • Significant cognitive impairment.
  • Active malignancy other than non-melanoma skin cancer.
  • Planned surgery (more than a minor one) in the next 30 days.
  • Patient has a known hypersensitivity to device materials (Nickel, suture material).
  • Moribund patient or patient with severe or deteriorating damage in critical body systems.
  • Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.
  • Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints.

Treatment and study plan

NeuGuide™ System

Device

The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.

Other names: transvaginal sacrospinous ligament fixation

Primary outcomes

  1. A composite of the Pelvic Organ Prolapse Quantification (POP-Q) C point score, patient-rated symptom of vaginal bulging after vaginal colpopexy performed using the NeuGuide™ and the absence of further surgical therapy for uterine prolapse.

    Time frame: 12 months

    Primary composite performance outcome

  2. The number of device / procedure related Serious Adverse Events (SAE).

    Time frame: 30 days

    Primary safety of surgical implantation as reflected by adverse events

  3. The number of Serious Adverse Events and Adverse Events.

    Time frame: 12 months

    Primary safety of NeuGuide treatment as reflected by adverse events

Secondary outcomes

  1. Change in mean POP-Q C point score from baseline (cm).

    Time frame: one month

    Secondary anatomical performance of the NeuGuide treatment

  2. Change in mean POP-Q C point score from baseline (cm).

    Time frame: 6 months

    Secondary anatomical performance of the NeuGuide treatment

  3. Change in mean POP-Q C point score from baseline (cm).

    Time frame: 12 months

    Secondary anatomical of the NeuGuide treatment

  4. Change in mean POP-Q C point score from baseline (cm).

    Time frame: 24 months

    Secondary anatomical performance of the NeuGuide treatment outcome

  5. Change in mean POP-Q C point score from baseline (cm).

    Time frame: 36 months

    Secondary anatomical performance of the NeuGuide treatment

  6. Number of subjects who require surgical therapy of uterine prolapse or urinary incontinence.

    Time frame: 36 months

    Secondary performance: durability of the NeuGuide treatment

  7. Number of subjects in whom the primary symptomatic reason for repair of prolapse persists.

    Time frame: 12 months

    Secondary symptomatic performance of the NeuGuide treatment

  8. The time utilization of staff performing the NeuGuide procedure.

    Time frame: one month

    Secondary outcome: Cost performance of the procedure

  9. The POP-Q Stage Score calculated from POP-Q measurements, where the Stages of POP-Q system measurement are as follows: Stage 0 no prolapse is demonstrated Stage 1 the most distal portion of the prolapse is more than 1 cm above the level of the hymen

    Time frame: Baseline

    Secondary outcome: POP-Q Stage Score.

  10. The POP-Q Stage Score calculated from POP-Q measurements, where the Stages of POP-Q system measurement are as follows: Stage 0 no prolapse is demonstrated Stage 1 the most distal portion of the prolapse is more than 1 cm above the level of the hymen

    Time frame: one month

    Secondary outcome: POP-Q Stage Score.

  11. The POP-Q Stage Score calculated from POP-Q measurements, where the Stages of POP-Q system measurement are as follows: Stage 0 no prolapse is demonstrated Stage 1 the most distal portion of the prolapse is more than 1 cm above the level of the hymen

    Time frame: 12 months

    Secondary outcome: POP-Q Stage Score.

  12. The POP-Q Stage Score calculated from POP-Q measurements, where the Stages of POP-Q system measurement are as follows: Stage 0 no prolapse is demonstrated Stage 1 the most distal portion of the prolapse is more than 1 cm above the level of the hymen

    Time frame: 24 months

    Secondary outcome: POP-Q Stage Score.

  13. The POP-Q Stage Score calculated from POP-Q measurements, where the Stages of POP-Q system measurement are as follows: Stage 0 no prolapse is demonstrated Stage 1 the most distal portion of the prolapse is more than 1 cm above the level of the hymen

    Time frame: 36 months

    Secondary outcome: POP-Q Stage Score.

Sponsors and collaborators

Lead sponsor

Pop Medical Solutions

Industry

Registry information

Official study title

The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse Post-Market Surveillance Clinical Study

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Feb 19, 2018
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.